Sort by 'likes'
Diagnosing Aggressive Forms of Prostate Cancer With New Imaging Tests and Biomarkers
On this show we have the Associate Director, Department of Urology, Roswell Park Cancer Institute Dr. James Mohler discussing the recent NCCN guidelines for prostate cancer treatment and the latest research available to us that can help diagnose high risk…
Myeloma: 2016 Year in Review and Outlook for 2017
The treatment options for myeloma continued to evolve in 2016 with new agents, immune based therapies and repurposing of existing approved agents. High-dose therapy and autologous stem cell transplantation remain the backbone of upfront treatment in myeloma. We are talking…
What’s New in Multiple Myeloma Management?
Multiple myeloma is diagnosed in over 100,000 patients each year worldwide. The FDA recently granted accelerated approval to Teclistamab, the first bispecific B-cell maturation (BCMA)-directed CD3 T-cell engager. The therapeutic armamentarium for myeloma now includes alkylating agents, corticosteroids, deacetylase inhibitors,…
Post-Transplant Outcomes in High Risk Multiple Myeloma
Treatment of patients with myeloma has changed dramatically in the past years due to development of new agents and myeloma specific targets. Despite these advancements, long term benefits remains less clear in high-risk multiple myeloma patients. Myeloma is classified as…
CRISPR-edited Immune Cells Enhance Fight Against Blood Cancers
The Nobel prize winning CRISPR-Cas9 genome editing system is being explored for its potential use in cancer research and treatment. By deleting, inactivating, or otherwise modifying specific genes in cultured cells or in animal models, researchers have been able to…